Skip to main content

Analysis

AMA Announces New CPT Codes for COVID-19 Immunizations

By Revenue Cycle Advisor  
   November 17, 2020

These new CPT codes will allow healthcare providers to report and track the administration of these COVID-19 vaccines once they receive approval or an emergency use authorization from the Food and Drug Administration.

A version of this article was first published November 16, 2020, by HCPro's Revenue Cycle Advisor, a sibling publication to HealthLeaders.

The American Medical Association (AMA) on November 10 announced a handful of new CPT codes for reporting COVID-19 vaccine products and immunization administration.

The code release includes two vaccine product codes and four vaccine administration codes. 

These new CPT codes will allow healthcare providers to report and track the administration of these COVID-19 vaccines once they receive approval or an emergency use authorization from the Food and Drug Administration. The codes will go into effect at that time.

The vaccine codes are linked to products manufactured by Pfizer Inc. and Moderna Inc. They are:

  • 91300, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use
    • Vaccine manufacturer: Pfizer Inc.
  • 91301, SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use
    • Vaccine manufacturer: Moderna Inc.

Each vaccine product code is linked with a pair of vaccine administration codes, which correspond to first and second doses.

For the 91300 product code, providers would report:

  • 0001A, immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose
  • 0002A, …; second dose

For the 91301 product code, providers would report:

  • 0011A, immunization administration by intramuscular injection of SARS-CoV-2 (COVID-19) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose
  • 0012A, …; second dose

The AMA says that it is critical that the codes “are available prior to the public availability of the vaccines to facilitate updating of healthcare electronic systems across the U.S.”

Revenue Cycle Advisor combines all of HCPro's Medicare regulatory and reimbursement resources into one handy and easy-to-access portal. News is not just repeated from other sources. It is analyzed by our Medicare experts so professionals can comprehend any new rule and regulatory updates thoroughly. Learn more.


Get the latest on healthcare leadership in your inbox.